Results 31 to 40 of about 8,856 (183)

Arteritis temporal. Revisión de la literatura

open access: yesRevista Habanera de Ciencias Médicas, 2013
Introducción: La arteritis temporal constituye una arteritis de células gigantes, la más común en la población en la población mayor de 50 años y usualmente mal diagnosticada. Objetivo: Mostrar elementos novedosos en el diagnóstico, presentación clínica,
Rafael Ángel Castañeda Barbán   +1 more
doaj  

Giant Cell Arteritis Presenting With Ocular Symptoms: Clinical Characteristics and Multimodal Imaging in a Chinese Case Series

open access: yesFrontiers in Medicine, 2022
PurposeTo evaluate demographic and clinical characteristics of a Chinese population with giant cell arteritis using multimodal imaging focusing on ophthalmic examinations.DesignRetrospective observational case series.Materials and MethodsIn the neuro ...
Qian Chen   +10 more
doaj   +1 more source

Timing and duration of glucagon‐like peptide‐1 receptor agonist use and risk of nonarteritic anterior ischaemic optic neuropathy

open access: yesActa Ophthalmologica, EarlyView.
Abstract Purpose To investigate the association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) use and nonarteritic anterior ischaemic optic neuropathy (NAION) in type 2 diabetes, examining treatment recency and cumulative duration. Methods This nationwide registry‐based nested case–control study utilizedz Danish health registries (1996 ...
Siar Niazi   +9 more
wiley   +1 more source

Myocardial Infarction Due to Giant Cell Arteritis: A Case Report and Literature Review

open access: yesKaohsiung Journal of Medical Sciences, 2007
Giant cell arteritis occurs mainly in the cranial arteries, especially in the temporal area, and rarely in the coronary arteries. Here, we present a case of coronary artery giant cell arteritis in a 51-year-old woman who complained of atypical chest pain.
Long-Wei Lin   +2 more
doaj   +1 more source

Cardiovascular toxicity from immune checkpoint inhibitor therapy: an inflammatory continuum

open access: yesBritish Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI) therapy has markedly improved outcomes in advanced malignancies but has also revealed a distinct spectrum of cardiovascular immune‐related adverse events. Myocarditis represents the most severe manifestation, while non‐inflammatory left ventricular dysfunction and vascular inflammation have emerged as additional ...
Fabrice Reyes   +7 more
wiley   +1 more source

Pulmonary nodules in a patient with Giant Cell Arteritis

open access: yesPulmonology, 2019
Giant Cell Arteritis (GCA) is a common systemic vasculitis that involves medium and large arteries, most frequently extracranial branches of the carotid artery.
D. Pinho dos Santos   +4 more
doaj   +1 more source

Scalp Necrosis Revealing Severe Giant-Cell Arteritis

open access: yesCase Reports in Medicine, 2020
Giant-cell arteritis (GCA), also referred to as temporal arteritis, is the most common primary vasculitis of the elderly involving the extracranial branches of the carotid arteries, in particular, the temporal artery.
Safa Idoudi   +7 more
doaj   +1 more source

Squamoid Eccrine Ductal Carcinoma: Case Series of a Rare, Potentially Aggressive Skin Cancer Associated With Immunosuppression

open access: yesJournal of Cutaneous Pathology, EarlyView.
ABSTRACT Squamoid Eccrine Ductal Carcinoma (SEDC) is a rare cutaneous adenexal carcinoma first described in 1997. It has distinct biphasic features on histology which commonly result in misdiagnosis as Bowen disease or cutaneous squamous cell carcinomas (cSCC) if diagnostic skin biopsies are too superficial. This may lead to a delay in diagnosis. It is
Xiang Li Tan   +15 more
wiley   +1 more source

Temporal Arteritis: Treatment Controversies

open access: yesNeurología (English Edition), 2010
Introduction: Although giant cell or temporal arteritis represents 5–10% of ischaemic optic neuropathies and is the most common arteritis in people over 60 years old.
J. Balsalobre Aznar, J. Porta-Etessam
doaj   +1 more source

Absence of Interaction Between 5α‐Reductase Inhibitors and Glucocorticoids on Incidence of Myocardial Infarction in People With Type 2 Diabetes

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims People with Type 2 diabetes experience higher cardiometabolic risk, and both synthetic glucocorticoids and use of 5α‐reductase inhibitors have been individually linked to increased risk of myocardial infarction. We tested whether the increase in risk is exacerbated by co‐prescription of both drugs.
Haolan Tu   +20 more
wiley   +1 more source

Home - About - Disclaimer - Privacy